{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:36:54Z","timestamp":1792813014432,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012638","name":"Valerion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015391","name":"Myositis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015461","name":"Audentes Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jns.2021.118074","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T10:46:19Z","timestamp":1631529979000},"page":"118074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis"],"prefix":"10.1016","volume":"430","author":[{"given":"Gil I.","family":"Wolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Sally","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"de Haard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ulrichts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Pasnoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gestur","family":"Vidarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.118074_bb0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An Fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jns.2021.118074_bb0010","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1084\/jem.180.6.2377","article-title":"A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus","volume":"180","author":"Story","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2021.118074_bb0015","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.4049\/jimmunol.151.11.6076","article-title":"Mouse MHC class I-like Fc receptor encoded outside the MHC","volume":"151","author":"Ahouse","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/eji.1830150718","article-title":"Isolation and characterization of an Fc receptor from neonatal rat small intestine","volume":"15","author":"Simister","year":"1985","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0025","doi-asserted-by":"crossref","first-page":"159s","DOI":"10.1083\/jcb.99.1.159s","article-title":"Receptor-mediated transport of IgG","volume":"99","author":"Rodewald","year":"1984","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jns.2021.118074_bb0030","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.4049\/jimmunol.157.8.3317","article-title":"Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal- fetal antibody transport","volume":"157","author":"Leach","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0035","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/intimm\/13.8.993","article-title":"The MHC class I related receptor, FcRn, plays an essential role in the maternofetal transfer of gammaglobulin in humans","volume":"13","author":"Firan","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0045","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the \u03b22-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2021.118074_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.20020400","article-title":"Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung","volume":"196","author":"Spiekermann","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2021.118074_bb0055","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.4049\/jimmunol.166.5.3266","article-title":"MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells","volume":"166","author":"Zhu","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0060","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.4049\/jimmunol.179.7.4580","article-title":"Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism","volume":"179","author":"Akilesh","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1369\/0022155417705095","article-title":"Distribution of FcRn across species and tissues","volume":"65","author":"Latvala","year":"2017","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.jns.2021.118074_bb0070","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1172\/JCI6968","article-title":"Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line","volume":"104","author":"Dickinson","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jns.2021.118074_bb0075","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/intimm\/10.9.1289","article-title":"Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice","volume":"10","author":"Borvak","year":"1998","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0080","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.172.4.2021","article-title":"Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn","volume":"172","author":"Ober","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jconrel.2018.07.023","article-title":"Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement","volume":"287","author":"Larsen","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jns.2021.118074_bb0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2133\/dmpk.24.318","article-title":"The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics","volume":"24","author":"Andersen","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jns.2021.118074_bb0095","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00084a037","article-title":"The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release","volume":"32","author":"Raghavan","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.jns.2021.118074_bb0100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","article-title":"Neonatal Fc receptor: from immunity to therapeutics","volume":"30","author":"Kuo","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0105","first-page":"249","article-title":"FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions","volume":"382","author":"Challa","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0110","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1091\/mbc.e03-11-0832","article-title":"Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fc-\u03b3 receptor","volume":"15","author":"Claypool","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jns.2021.118074_bb0115","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.immuni.2004.05.007","article-title":"Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells","volume":"20","author":"Yoshida","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.jns.2021.118074_bb0120","doi-asserted-by":"crossref","first-page":"11076","DOI":"10.1073\/pnas.0402970101","article-title":"Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level","volume":"101","author":"Ober","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2021.118074_bb0125","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1073\/pnas.0700337104","article-title":"Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy","volume":"104","author":"Prabhat","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2021.118074_bb0130","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI106279","article-title":"Metabolic properties of IgG subclasses in man","volume":"49","author":"Morell","year":"1970","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jns.2021.118074_bb0135","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jns.2021.118074_bb0145","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0150","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6","article-title":"Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn","volume":"29","author":"Kim","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxg018","article-title":"Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans","volume":"15","author":"Ward","year":"2003","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0160","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jps.24136","article-title":"Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation","volume":"104","author":"Gao","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jns.2021.118074_bb0165","first-page":"135","article-title":"Methionine oxidation and aging","volume":"2005","author":"Stadtman","year":"1703","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jns.2021.118074_bb0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2021.118074_bb0175","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/eji.200636556","article-title":"The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin","volume":"36","author":"Andersen","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0180","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/bi052628y","article-title":"Albumin binding to FcRn: distinct from the FcRn-IgG interaction","volume":"45","author":"Chaudhury","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.jns.2021.118074_bb0185","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","article-title":"A human endothelial cell-based recycling assay for screening of FcRn targeted molecules","volume":"9","author":"Grevys","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jns.2021.118074_bb0190","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1074\/jbc.M113.537563","article-title":"Structural insights into neonatal Fc receptor-based recycling mechanisms","volume":"289","author":"Oganesyan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2021.118074_bb0195","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jns.2021.118074_bb0200","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.118074_bb0205","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4","article-title":"A pathogenic autoantibody, pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes","volume":"29","author":"Aoyama","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12185-013-1370-4","article-title":"Pathophysiology and management of primary immune thrombocytopenia","volume":"98","author":"Kashiwagi","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jns.2021.118074_bb0215","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JND-170294","article-title":"New pathways and therapeutic targets in autoimmune myasthenia gravis","volume":"5","author":"Behin","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.jns.2021.118074_bb0220","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.118074_bb0225","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2021.118074_bb0230","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis A","volume":"505","author":"Engel","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2021.118074_bb0235","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2021.118074_bb0240","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2021.118074_bb0245","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2021.118074_bb0250","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21694","article-title":"Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status","volume":"34","author":"Usmani","year":"2019","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.jns.2021.118074_bb0255","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/GRF.0b013e31828e92c0","article-title":"Myasthenia gravis and pregnancy","volume":"56","author":"Varner","year":"2013","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.jns.2021.118074_bb0260","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2021.118074_bb0265","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jns.2021.118074_bb0270","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1537-2995.1982.22182154218.x","article-title":"Changes in coagulation factors, complement, immunoglobulins, and immune complex concentrations with plasma exchange","volume":"22","author":"Volkin","year":"1982","journal-title":"Transfusion"},{"key":"10.1016\/j.jns.2021.118074_bb0275","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1529-8027.2010.00263.x","article-title":"Long-term regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy","volume":"15","author":"Isose","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jns.2021.118074_bb0280","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/jnnp.57.5.578","article-title":"Immunoadsorption therapy for myasthenia gravis","volume":"57","author":"Shibuya","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.118074_bb0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0972-5229.148631","article-title":"Therapeutic plasma exchange in the treatment of myasthenia gravis","volume":"19","author":"Kumar","year":"2015","journal-title":"Indian J. Crit. Care Med."},{"key":"10.1016\/j.jns.2021.118074_bb0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.jns.2021.118074_bb0295","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jns.2021.118074_bb0300","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/0090-1229(89)90073-1","article-title":"Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis","volume":"53","author":"Zweiman","year":"1989","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.jns.2021.118074_bb0305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2021.118074_bb0310","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0315","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2021.118074_bb0320","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2021.118074_bb0325","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0330","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1073\/pnas.89.13.6070","article-title":"Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses","volume":"89","author":"Spriggs","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jns.2021.118074_bb0335","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0340","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1073\/pnas.89.13.6070","article-title":"Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses","volume":"89","author":"Spriggs","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2021.118074_bb0345","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jaci.2014.12.1937","article-title":"\u03b22-microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system","volume":"136","author":"Ardeniz","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0350","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1073\/pnas.0600548103","article-title":"Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene","volume":"103","author":"Wani","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2021.118074_bb0355","series-title":"Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderate-to-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study (S43. 001). AAN Enterprises","author":"Bril","year":"2019"},{"key":"10.1016\/j.jns.2021.118074_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jns.2021.118074_bb0365","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jps.20297","article-title":"Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions","volume":"94","author":"Getman","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jns.2021.118074_bb0370","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0375","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jns.2021.118074_bb0380","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jns.2021.118074_bb0385","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2015.02.007","article-title":"Targeting FcRn for the modulation of antibody dynamics","volume":"67","author":"Ward","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0390","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.118074_bb0395","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2021.118074_bb0400","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1073\/pnas.0708960105","article-title":"Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn","volume":"105","author":"Mezo","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jns.2021.118074_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jns.2021.118074_bb0410","series-title":"Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)","author":"Momenta","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0415","series-title":"Vivacity MG Phase 2 Interim Analysis Topline Results. Investor and Analyst Conference Call ed","author":"Momenta, Pharmaceuticals, Inc","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0420","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/trf.12334","article-title":"H435-containing immunoglobulinG3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn","volume":"54","author":"Einarsdottir","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.jns.2021.118074_bb0425","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/intimm\/13.8.993","article-title":"The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans","volume":"13","author":"Firan","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0430","series-title":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)","author":"ClinicalTrials.gov","year":"2019"},{"key":"10.1016\/j.jns.2021.118074_bb0435","series-title":"Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia","author":"ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0440","article-title":"Intravenous immune globulin uses in the fetus and neonate: a review","volume":"9","author":"Alsaleem","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jns.2021.118074_bb0445","first-page":"126","article-title":"A randomized, double-blind, placebo-controlled investigation of the safety of intravenous immune globulin administration to preterm neonates","volume":"9","author":"Christensen","year":"1989","journal-title":"J. Perinatol."},{"key":"10.1016\/j.jns.2021.118074_bb0450","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange","volume":"317","author":"Van der Neut","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jns.2021.118074_bb0455","article-title":"Phase II, multiple-dose study of anti-FcRn antibody, rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: interim analysis","volume":"130","author":"Robak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jns.2021.118074_bb0460","series-title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy1)","author":"ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0465","series-title":"A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (MyCIDPchoice)","author":"ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0470","series-title":"UCB Full Year Report 2020: UCB - Sustaining Growth, Now and Into the Future","author":"UCB","year":"2021"},{"key":"10.1016\/j.jns.2021.118074_bb0475","series-title":"RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5. 2\u2013079). AAN Enterprises","author":"Collins","year":"2019"},{"key":"10.1016\/j.jns.2021.118074_bb0480","series-title":"ASCEND MG Topline Results Conference Call","author":"Immunovant","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0485","series-title":"ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )","author":"ClinicalTrials.gov","year":"2019"},{"key":"10.1016\/j.jns.2021.118074_bb0490","series-title":"To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). (ASCEND-WAIHA)","author":"ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0495","unstructured":"Immunovant."},{"key":"10.1016\/j.jns.2021.118074_bb0500","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.jns.2021.118074_bb0505","series-title":"A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)","author":"ClinicalTrials.gov","year":"2018"},{"key":"10.1016\/j.jns.2021.118074_bb0510","series-title":"argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis","author":"argenx","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0515","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.118074_bb0520","series-title":"A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)","author":"ClinicalTrials.gov","year":"2019"},{"key":"10.1016\/j.jns.2021.118074_bb0525","series-title":"A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.jns.2021.118074_bb0530","series-title":"A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)","author":"ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0535","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0540","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.118074_bb0545","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2021.118074_bb0550","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.vaccine.2021.03.075","article-title":"Lack of neonatal fc receptor does not diminish the efficacy of the HSV-1 0\u0394NLS vaccine against ocular HSV-1 challenge","volume":"39","author":"Carr","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jns.2021.118074_bb0555","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.4049\/jimmunol.1302461","article-title":"Cell contact\u2013dependent priming and fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response","volume":"192","author":"Bartholomaeus","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2021.118074_bb0560","series-title":"A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","author":"ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.jns.2021.118074_bb0565","series-title":"A Study of RVT-1401 in Myasthenia Gravis (MG) Patients","author":"ClinicalTrials.gov","year":"2019"},{"key":"10.1016\/j.jns.2021.118074_bb0570","series-title":"Rare Neurological Disease Special Report: Supplement to Neurology Reviews","first-page":"34","article-title":"The therapeutic potential for FcRn blockade in myasthenia gravis - antibodies and antibody clearance","author":"Habib","year":"2020"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2100770X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2100770X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:55:38Z","timestamp":1758383738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2100770X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":114,"alternative-id":["S0022510X2100770X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.118074","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.118074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 argenx. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"118074"}}